News

Emerging scientific evidence suggests that cannabinoids such as CBD, CBG, and CBN offer promising therapeutic potential for managing Complex Regional Pain Syndrome (CRPS) and myxofibrosarcoma. CBD has demonstrated anti-inflammatory, analgesic, and anticancer properties, making it valuable for chronic pain and tumor inhibition. CBG shows strong neuroprotective and antiproliferative effects, particularly in neuropathic pain and colorectal cancer models. CBN, primarily recognized for its sedative qualities, has been clinically shown to improve sleep quality without causing next-day fatigue and may also possess cytotoxic effects against cancer cells. While dosing varies, higher levels—such as 200 mg+ of CBD and 20 mg of CBN—are increasingly used in clinical settings. Continued research is essential, but cannabinoids stand as a compelling adjunctive therapy for patients seeking integrative options.